Results 11 to 20 of about 390,088 (309)

Flexible Loading Phase Treat-and-Extend Regimen with Faricimab for Neovascular Age-Related Macular Degeneration: A Real-World Study [PDF]

Biomedicines
Background/Objectives: We aimed to evaluate the efficacy of a flexible loading-phase treat-and-extend regimen using faricimab, in which the number of loading-phase intravitreal injections was tailored to individual disease activity.
Akira Machida, Junko Kurihara, Yuki Hirata, Eriko Machida, Ryuya Murakami, Akari Oka, Ai Yoneda, Eiko Tsuiki, Akio Oishi   +8 more
doaj   +6 more sources

Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis [PDF]

Ophthalmology and Therapy, 2022
Recently, there has been growing interest in exploring the relationship between visual acuity and fluid localization in different retinal compartments.
V. Chaudhary, F. Holz, S. Wolf, E. Midena, E. Souied, Helmut Allmeier, G. Lambrou, Tobias Machewitz, P. Mitchell   +8 more
semanticscholar   +4 more sources

Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion

Ophthalmic Surgery, Lasers and Imaging Retina, 2014
BACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO)–associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 ...
Rush, R, Simunovic, M, Aragon, A, Ysasaga, J   +3 more
openaire   +4 more sources

EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION [PDF]

Retina, 2019
Purpose: To evaluate the outcome of an exit strategy in a treat-and-extend regimen for neovascular age-related macular degeneration. Methods: Five hundred and ninety-eight eyes of 488 patients with neovascular age-related macular ...
Arendt P, Yu S, Munk MR, Ebneter A, Wolf S, Zinkernagel MS   +5 more
core   +6 more sources

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. [PDF]

Ophthalmol Ther
Reducing intravitreal injection frequency while maintaining efficacy is a critical goal in alleviating the burden associated with anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema (DME) or neovascular age ...
Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, Chan K, Leng T, Patel N.   +8 more
europepmc   +2 more sources

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration

International Journal of Retina and Vitreous, 2021
Purpose To investigate the visual and anatomical outcomes associated with treat-and-extend (TAE) regimen of intravitreal (IVT) aflibercept in eyes with treatment naïve neovascular age-related macular degeneration (nvAMD).
Mohamed Kamel Soliman, Nicolas Tuli, Thomas K. Lee, William A. Britton, Raman Tuli   +4 more
doaj   +2 more sources

A post-hoc analysis of intravitreal aflibercept-treated nAMD patients from ARIES & ALTAIR: predicting treatment intervals and frequency for aflibercept treat-and-extend therapy regimen using machine learning. [PDF]

Graefes Arch Clin Exp Ophthalmol
To predict potential treatment need during treat-and-extend (T&E) anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) using an artificial intelligence (AI) model trained using transfer learning.
Gutfleisch M, Heimes-Bussmann B, Aydin S, Petrovic R, Loktyushin A, Ohji M, Takahashi K, Okada AA, Scholz P, Youssef H, Bauer-Steinhusen U, Machewitz T, Rothaus K, Lommatzsch A.   +13 more
europepmc   +2 more sources

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR

Advances in Therapy, 2020
Purpose To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related macular degeneration (AMD).
Kanji Takahashi, Annabelle Okada, Mio Hosokawa   +2 more
exaly   +2 more sources

One-Year Outcomes of Aflibercept in Treat-and-Extend Versus Pro Re Nata Regimens for Bevacizumab-Resistant Diabetic Macular Edema: A Real-World Study. [PDF]

Ophthalmol Ther
The aim of this study was to compare the efficacy of the treat-and-extend (TAE) regimen versus the pro re nata (PRN) regimen in patients with bevacizumab-resistant diabetic macular edema (DME) treated with aflibercept, with or without adjunctive laser ...
Yozgat Z, Isik MU, Sabaner MC.
europepmc   +2 more sources

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

Ophthalmology and Therapy, 2020
Introduction To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-and-extend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Methods Fifty-
Tomoko Tamachi, Takeya Kohno, Manabu Yamamoto, Kumiko Hirayama, Akika Kyo, Nobuhiko Ueda, Michiko Hirabayashi, Kunihiko Shiraki, Shigeru Honda   +8 more
doaj   +2 more sources